JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients

被引：0
|
作者：
Basnyat, P. [1 ]
Virtanen, E. [2 ,3 ]
Elovaara, I. [1 ,4 ]
Hagman, S. [1 ]
Auvinen, E. [2 ,3 ]
机构：
[1] Univ Tampere, Sch Med, Neuroimmunol Unit, Tampere, Finland
[2] Medicum, Dept Virol, Helsinki, Finland
[3] Univ Helsinki, Helsinki Univ Hosp Lab, Helsinki, Finland
[4] Tampere Univ Hosp, Dept Neurol, Tampere, Finland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1610
引用
收藏
页码：843 / 843
页数：1
相关论文
共 50 条
  • [1] JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients
    Pabitra Basnyat
    Elina Virtanen
    Irina Elovaara
    Sanna Hagman
    Eeva Auvinen
    [J]. Journal of NeuroVirology, 2017, 23 : 734 - 741
  • [2] JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients
    Basnyat, Pabitra
    Virtanen, Elina
    Elovaara, Irina
    Hagman, Sanna
    Auvinen, Eeva
    [J]. JOURNAL OF NEUROVIROLOGY, 2017, 23 (05) : 734 - 741
  • [3] Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis
    Bridel, Claire
    Leurs, Cyra E.
    van Lierop, Zoe Y. G. J.
    van Kempen, Zoe L. E.
    Dekker, Iris
    Twaalfhoven, Harry A. M.
    Moraal, Bastiaan
    Barkhof, Frederik
    Uitdehaag, Bernard M. J.
    Killestein, Joep
    Teunissen, Charlotte E.
    [J]. NEUROLOGY, 2021, 97 (19) : E1898 - E1905
  • [4] JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients
    Agostini, Simone
    Mancuso, Roberta
    Costa, Andrea Saul
    Caputo, Domenico
    Clerici, Mario
    [J]. VIRUSES-BASEL, 2021, 13 (03):
  • [5] Long-term effect of natalizumab in relapsing-remitting multiple sclerosis: TYSTEN cohort
    Bigaut, K.
    Fabacher, T.
    Kremer, L.
    Ongagna, J. -C.
    Kwiat-Kowski, A.
    Sellal, F.
    Ferriby, D.
    Courtois, S.
    Vermersch, P.
    Collongues, N.
    Zephir, H.
    De Seze, J.
    Outteryck, O.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 536 - 536
  • [6] Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
    van Lierop, Zoe Y. G. J.
    Noteboom, Samantha
    Steenwijk, Martijn D.
    van Dam, Maureen
    Toorop, Alyssa A.
    Kempen, Zoe L. E. van
    Moraal, Bastiaan
    Barkhof, Frederik
    Uitdehaag, Bernard M. J.
    Schoonheim, Menno M.
    Teunissen, Charlotte E.
    Killestein, Joep
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (14) : 2231 - 2242
  • [7] Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab
    Dekker, I
    Leurs, C. E.
    Hagens, M. H. J.
    van Kempen, Z. L. E.
    Kleerekooper, I
    Lissenberg-Witte, B., I
    Barkhof, F.
    Uitdehaag, B. M. J.
    Balk, L. J.
    Wattjes, M. P.
    Killestein, J.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 33 : 82 - 87
  • [8] Neurocognitive changes in patients with relapsing-remitting multiple sclerosis treated with natalizumab
    Doehler, N.
    Mueller, S.
    Vehoff, J.
    Galovic, M.
    Tettenborn, B.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 213 - 213
  • [9] Author Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis
    Bridel, Claire
    Killestein, Joep
    Teunissen, Charlotte
    [J]. NEUROLOGY, 2022, 98 (11) : 471 - 471
  • [10] Improved or maintained employment status in natalizumab-treated relapsing-remitting multiple sclerosis patients in the tysabri observational program
    Kobelt, G.
    Trojano, M.
    Spelman, T.
    Butzkueven, H.
    Kappos, L.
    Wiendl, H.
    Liao, S.
    Acosta, C.
    Ho, P. -R.
    Licata, S.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 609 - 610
12345